OPKO acquires dry eye treatment

Article

OPKO Health has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound, civamide, with potential applications for the treatment of dry eye.

OPKO Health has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound, civamide, with potential applications for the treatment of dry eye.

The compound is a proprietary TRPV-1 receptor modulator and neuronal calcium channel blocker and is currently undergoing Phase III clinical trials, as an intra-nasal formulation, to treat various types of pain. Increased tear production was observed in over 50% of the trial patients receiving civamide and no systemic side effects were recorded. Preliminary investigations suggest that civamide's effects on tear production result from its ability to modify signal transduction pathways present in the human lacrimal gland.

Terms of the agreement have not been disclosed.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.